

# Reportable Segment Changes

June 5, 2026

# Cautionary Statement Regarding Forward-Looking Information

Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this presentation may include, without limitation, statements regarding (i) the change in the Company's reportable segments, and prospective supplemental disclosures within this framework; (ii) estimates or projections of future financial results, financial condition, capital expenditures, capital structure or other financial items; and (iii) the assumptions underlying or relating to any statement described in points (i) and (ii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties.


Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, availability and demand for the Company's products; the Company's ability to successfully develop and market new products and technologies; the impact of competitive products and pricing; product quality; disruptions caused by cybersecurity events; any failure to realize the anticipated strategic benefits and opportunities from acquisitions and divestitures; pricing pressures resulting from trends toward healthcare cost containment and the effect of industry consolidation; manufacturing, distribution and supply chain disruptions and cost increases; the Company's ability to implement as planned and realize estimated cost savings from the market and regional alignment initiative; the effects of global economic and political conditions, including changing trade and tariff policies and inflationary pressures; regulatory uncertainties, including in the receipt or timing of regulatory approvals, and the impact of changes in global regulatory conditions; indebtedness incurred by the Company, including the conditional conversion feature of its convertible notes; the Company's ability to protect its intellectual property; litigation; and the impact of share repurchases on the Company's stock price and volatility as well as the effect of short-term price fluctuations on the share repurchase program's effectiveness. These and other factors are identified and described in more detail in the Company's periodic reports and other filings with the U.S. Securities and Exchange Commission (the "SEC"). The Company does not undertake to update these forward-looking statements.

# Summary of Reportable Segment Changes

## EXECUTIVE SUMMARY

- Reportable segments simplified from three to two, aligning external reporting with the Company's management structure.
- Plasma and Blood Center combined into Apheresis; Hospital renamed MedSurg.
- Supplemental revenue disclosures retained: Apheresis (Plasma and Other) and MedSurg (Blood Management Technologies and Interventional Technologies).
- New reporting structure effective Q1 FY27.
- Historical revenue results and FY27 organic growth guidance recast to reflect the new structure<sup>5</sup>.

## FY'26 Revenue New Reportable Segments with Supplemental Disclosures



1) Plasma includes Plasma product line. 2) Other includes Platelets, Red Cells, and other product lines. 3) Blood Management Technologies includes Hemostasis Management, Cell Salvage, and Transfusion Management product lines. 4) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies, and Esophageal Protection product lines. 5) This presentation recasts the fiscal 2027 revenue guidance issued on May 7, 2026, solely to reflect the new reportable segment structure. It does not constitute a reaffirmation or update of the Company's previously issued guidance. Any future updates, if any, will be provided on the Company's first-quarter fiscal year 2027 earnings call.

# Fiscal 2027 Guidance Recast To New Reportable Segment Structure

This presentation recasts the fiscal 2027 revenue guidance issued on May 7, 2026, solely to reflect the new reportable segment structure. It does not constitute a reaffirmation or update of the Company's previously issued guidance. Any future updates, if any, will be provided on the Company's first-quarter fiscal year 2027 earnings call.

**Table 1. Fiscal 2027 Organic Revenue Growth Guidance issued May 7, 2026 (Recast to New Reportable Segment Structure)<sup>3</sup>**

	Prior Reportable Segments		New Reportable Segments
Plasma	~ MSD Growth	Apheresis	~LSD Growth <sup>1</sup>
Blood Center	~ MSD Decline	MedSurg	~ MSD Growth <sup>2</sup>
Hospital	~ MSD Growth <sup>2</sup>	<b>Total Company</b>	<b>3 – 6%<sup>2</sup></b>
<b>Total Company</b>	<b>3 – 6%<sup>2</sup></b>		

**Table 2. Fiscal 2027 Consolidated Guidance issued May 7, 2026 (Unchanged)**

<b>Reported Revenue</b>	<b>4 – 7%</b>	<b>Adjusted Operating Margin</b>	<b>50 – 100 bps expansion YoY</b>
53rd Week Impact	(~2%)	<b>Adjusted EPS</b>	<b>Comparable to revenue growth</b>
Currency Impact	0 – 1%	<b>Free cash flow conversion<sup>4</sup></b>	<b>~80%</b>
<b>Organic Revenue<sup>2</sup></b>	<b>3 – 6%</b>		

1) Organic revenue guidance for the new Apheresis segment reflects the combination of the Company's previously issued guidance for the Plasma and Blood Center segments and does not represent a change in underlying business assumptions or outlook. 2) Hospital/MedSurg and Total Company organic growth guidance includes nominal historical pre-acquisition revenue of Vivasure to provide a comparable view of period-over-period performance. 3) MSD stands for mid-single digits. LSD stands for low-single digits. 4) Free cash flow conversion is calculated as free cash flow divided by adjusted net income.

# Q4 Fiscal 2026 Reportable Segment Reconciliation with Supplemental Disclosures

**Table 1: Reconciliation of Prior and New Reportable Segment with Supplemental Disclosures**  
(Dollars in thousands)

	New Reportable Segments with Supplemental Disclosures						
	Apheresis			MedSurg			Total net revenues
	Plasma <sup>1</sup>	Other <sup>2</sup>	Sub-Total	Blood Management Technologies <sup>3</sup>	Interventional Technologies <sup>4</sup>	Sub-Total	
<b>Plasma</b>	\$ 130,290	-	\$ 130,290	-	-	-	\$ 130,290
<b>Blood center</b>	18,548	\$ 37,866	56,414	-	-	-	56,414
Apheresis	18,548	37,866	56,414	-	-	-	56,414
Whole Blood	-	-	-	-	-	-	-
<b>Hospital</b>	-	-	-	\$ 99,250	\$ 60,397	\$ 159,647	159,647
Blood Management Technologies	-	-	-	99,250	-	99,250	99,250
Interventional Technologies	-	-	-	-	60,397	60,397	60,397
<b>Total net revenues</b>	\$ 148,838	\$ 37,866	\$ 186,704	\$ 99,250	\$ 60,397	\$ 159,647	\$ 346,351

**Table 2: Revenue Analysis by New Reportable Segment and Supplemental Disclosures**  
(Dollars in thousands)

	Q4 FY26	Q4 FY25	Reported growth	Currency impact	Acquisitions & Divestitures <sup>5</sup>	Organic growth	CSL US Disposables Revenue <sup>6</sup>	Organic growth, ex-CSL
<b>Apheresis</b>	\$ 186,704	\$ 181,056	3.1%	1.2%	-0.9%	2.8%	-7.6%	10.4%
Plasma <sup>1</sup>	148,838	141,857	4.9%	1.3%	-1.2%	4.9%	-10.1%	15.0%
Other <sup>2</sup>	37,866	39,200	-3.4%	1.1%	-%	-4.5%	-%	-4.5%
<b>MedSurg</b>	159,647	147,857	8.0%	1.5%	-%	6.5%	-%	6.5%
Blood Management Technologies <sup>3</sup>	99,250	81,058	22.4%	2.0%	-%	20.5%	-%	20.5%
Interventional Technologies <sup>4</sup>	60,397	66,799	-9.6%	0.7%	-%	-10.3%	-%	-10.3%
<b>Whole Blood (divested)</b>	-	1,686	-100.0%	-%	-%	-100.0%	-%	-100.0%
<b>Total net revenues</b>	\$ 346,351	\$ 330,599	4.8%	1.3%	-1.0%	4.5%	-4.1%	8.6%

1) Plasma includes Plasma product line. 2) Other includes Platelets, Red Cells and other product lines. 3) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines. 4) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines. 5) Reflects the impact in Blood Center of the divestiture of the Whole Blood product line as of its completion in January 2025 and the impact of the exit of certain liquid solution products. 6) Reflects the impact in Plasma of fiscal 2025 disposable sales to CSL Plasma under its transitional U.S. supply agreement with the Company.

# Q3 Fiscal 2026 Reportable Segment Reconciliation with Supplemental Disclosures

**Table 1: Reconciliation of Prior and New Reportable Segment with Supplemental Disclosures**  
(Dollars in thousands)

	New Reportable Segments with Supplemental Disclosures						
	Apheresis			MedSurg			Total net revenues
	Plasma <sup>1</sup>	Other <sup>2</sup>	Sub-Total	Blood Management Technologies <sup>3</sup>	Interventional Technologies <sup>4</sup>	Sub-Total	
<b>Plasma</b>	\$ 138,905	-	\$ 138,905	-	-	-	\$ 138,905
<b>Blood center</b>	17,881	\$ 38,679	56,560	-	-	-	56,560
Apheresis	17,881	38,679	56,560	-	-	-	56,560
Whole Blood	-	-	-	-	-	-	-
<b>Hospital</b>	-	-	-	\$ 87,448	\$ 56,054	\$ 143,502	143,502
Blood Management Technologies	-	-	-	87,448	-	87,448	87,448
Interventional Technologies	-	-	-	-	56,054	56,054	56,054
<b>Total net revenues</b>	\$ 156,786	\$ 38,679	\$ 195,465	\$ 87,448	\$ 56,054	\$ 143,502	\$ 338,967

**Table 2: Revenue Analysis by New Reportable Segment and Supplemental Disclosures**  
(Dollars in thousands)

	Q3 FY26	Q3 FY25	Reported growth	Currency impact	Acquisitions & Divestitures <sup>5</sup>	Organic growth	CSL US Disposables Revenue <sup>6</sup>	Organic growth, ex-CSL
<b>Apheresis</b>	\$ 195,465	\$ 189,612	3.1%	0.9%	-0.6%	2.8%	-11.9%	14.7%
Plasma <sup>1</sup>	156,786	150,924	3.9%	0.8%	-0.7%	3.8%	-15.6%	19.4%
Other <sup>2</sup>	38,679	38,688	-%	1.1%	-%	-1.1%	-%	-1.1%
<b>MedSurg</b>	143,502	143,973	-0.3%	0.6%	-%	-0.9%	-%	-0.9%
Blood Management Technologies <sup>3</sup>	87,448	80,720	8.3%	0.7%	-%	7.6%	-%	7.6%
Interventional Technologies <sup>4</sup>	56,054	63,253	-11.4%	0.2%	-%	-11.6%	-%	-11.6%
<b>Whole Blood (divested)</b>	-	14,957	-100.0%	-%	-%	-100.0%	-%	-100.0%
<b>Total net revenues</b>	\$ 338,967	\$ 348,542	-2.7%	0.8%	-4.7%	1.2%	-6.3%	7.5%

1) Plasma includes Plasma product line. 2) Other includes Platelets, Red Cells and other product lines. 3) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines. 4) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines. 5) Reflects the impact in Blood Center of the divestiture of the Whole Blood product line as of its completion in January 2025 and the impact of the exit of certain liquid solution products. 6) Reflects the impact in Plasma of fiscal 2025 disposable sales to CSL Plasma under its transitional U.S. supply agreement with the Company.

# Q2 Fiscal 2026 Reportable Segment Reconciliation with Supplemental Disclosures

**Table 1: Reconciliation of Prior and New Reportable Segment with Supplemental Disclosures**  
(Dollars in thousands)

	New Reportable Segments with Supplemental Disclosures							
	Apheresis			MedSurg			Whole Blood (divested)	Total net revenues
	Plasma <sup>1</sup>	Other <sup>2</sup>	Sub-Total	Blood Management Technologies <sup>3</sup>	Interventional Technologies <sup>4</sup>	Sub-Total		
<b>Prior Reportable Segments with Supplemental Disclosures</b>								
<b>Plasma</b>	\$ 125,364	-	\$ 125,364	-	-	-	-	\$ 125,364
<b>Blood center</b>	14,250	\$ 41,815	56,065	-	-	-	\$ 389	56,454
Apheresis	14,250	41,815	56,065	-	-	-	-	56,065
Whole Blood	-	-	-	-	-	-	389	389
<b>Hospital</b>	-	-	-	\$ 86,424	\$ 59,073	\$ 145,497	-	145,497
Blood Management Technologies	-	-	-	86,424	-	86,424	-	86,424
Interventional Technologies	-	-	-	-	59,073	59,073	-	59,073
<b>Total net revenues</b>	\$ 139,614	\$ 41,815	\$ 181,429	\$ 86,424	\$ 59,073	\$ 145,497	\$ 389	\$ 327,315

**Table 2: Revenue Analysis by New Reportable Segment and Supplemental Disclosures**  
(Dollars in thousands)

	Q2 FY26	Q2 FY25	Reported growth	Currency impact	Acquisitions & Divestitures <sup>5</sup>	Organic growth	CSL US Disposables Revenue <sup>6</sup>	Organic growth, ex-CSL
<b>Apheresis</b>	\$ 181,429	\$ 192,893	-5.9%	0.9%	-0.5%	-6.3%	-20.1%	13.8%
Plasma <sup>1</sup>	139,614	154,819	-9.8%	0.8%	-0.7%	-10.0%	-25.4%	15.5%
Other <sup>2</sup>	41,815	38,074	9.8%	1.4%	-%	8.4%	-%	8.4%
<b>MedSurg</b>	145,497	138,422	5.1%	0.6%	-%	4.5%	-%	4.5%
Blood Management Technologies <sup>3</sup>	86,424	76,499	13.0%	0.8%	-%	12.2%	-%	12.2%
Interventional Technologies <sup>4</sup>	59,073	61,923	-4.6%	0.4%	-%	-5.0%	-%	-5.0%
<b>Whole Blood (divested)</b>	389	14,196	-97.3%	-%	2.0%	-99.2%	-%	-99.2%
<b>Total net revenues</b>	\$ 327,315	\$ 345,511	-5.3%	0.7%	-4.2%	-1.8%	-11.2%	9.4%

1) Plasma includes Plasma product line. 2) Other includes Platelets, Red Cells and other product lines. 3) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines. 4) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines. 5) Reflects the impact in Blood Center of the divestiture of the Whole Blood product line as of its completion in January 2025 and the impact of the exit of certain liquid solution products. 6) Reflects the impact in Plasma of fiscal 2025 disposable sales to CSL Plasma under its transitional U.S. supply agreement with the Company.

# Q1 Fiscal 2026 Reportable Segment Reconciliation with Supplemental Disclosures

**Table 1: Reconciliation of Prior and New Reportable Segment with Supplemental Disclosures**  
(Dollars in thousands)

	New Reportable Segments with Supplemental Disclosures							
	Apheresis			MedSurg			Whole Blood (divested)	Total net revenues
	Plasma <sup>1</sup>	Other <sup>2</sup>	Sub-Total	Blood Management Technologies <sup>3</sup>	Interventional Technologies <sup>4</sup>	Sub-Total		
<b>Prior Reportable Segments with Supplemental Disclosures</b>								
<b>Plasma</b>	\$ 129,897	-	\$ 129,897	-	-	-	-	\$ 129,897
<b>Blood center</b>	15,177	\$ 36,645	51,822	-	-	-	\$ 17	51,839
Apheresis	15,177	36,645	51,822	-	-	-	-	51,822
Whole Blood	-	-	-	-	-	-	17	17
<b>Hospital</b>	-	-	-	\$ 81,175	\$ 58,483	\$ 139,658	-	139,658
Blood Management Technologies	-	-	-	81,175	-	81,175	-	81,175
Interventional Technologies	-	-	-	-	58,483	58,483	-	58,483
<b>Total net revenues</b>	\$ 145,074	\$ 36,645	\$ 181,719	\$ 81,175	\$ 58,483	\$ 139,658	\$ 17	\$ 321,394

**Table 2: Revenue Analysis by New Reportable Segment and Supplemental Disclosures**  
(Dollars in thousands)

	Q1 FY26	Q1 FY25	Reported growth	Currency impact	Acquisitions & Divestitures <sup>5</sup>	Organic growth	CSL US Disposables Revenue <sup>6</sup>	Organic growth, ex-CSL
<b>Apheresis</b>	\$ 181,719	\$ 185,004	-1.8%	0.6%	-0.4%	-2.0%	-23.1%	21.1%
Plasma <sup>1</sup>	145,074	153,106	-5.2%	0.5%	-0.4%	-5.3%	-28.4%	23.1%
Other <sup>2</sup>	36,645	31,894	14.9%	0.9%	-%	13.9%	-%	13.9%
<b>MedSurg</b>	139,658	134,017	4.2%	0.4%	-%	3.8%	-%	3.8%
Blood Management Technologies <sup>3</sup>	81,175	70,974	14.4%	0.6%	-%	13.8%	-%	13.8%
Interventional Technologies <sup>4</sup>	58,483	63,044	-7.2%	0.3%	-%	-7.5%	-%	-7.5%
<b>Whole Blood (divested)</b>	17	17,151	-99.9%	-%	1.1%	-101.0%	-%	-101.0%
<b>Total net revenues</b>	\$ 321,394	\$ 336,172	-4.4%	0.5%	-5.4%	0.5%	-12.4%	12.9%

1) Plasma includes Plasma product line. 2) Other includes Platelets, Red Cells and other product lines. 3) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines. 4) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines. 5) Reflects the impact in Blood Center of the divestiture of the Whole Blood product line as of its completion in January 2025 and the impact of the exit of certain liquid solution products. 6) Reflects the impact in Plasma of fiscal 2025 disposable sales to CSL Plasma under its transitional U.S. supply agreement with the Company.

# Q4 Fiscal 2025 Reportable Segment Reconciliation with Supplemental Disclosures

**Table 1: Reconciliation of Prior and New Reportable Segment with Supplemental Disclosures**  
(Dollars in thousands)

	New Reportable Segments with Supplemental Disclosures							
	Apheresis			MedSurg			Whole Blood (divested)	Total net revenues
	Plasma <sup>1</sup>	Other <sup>2</sup>	Sub-Total	Blood Management Technologies <sup>3</sup>	Interventional Technologies <sup>4</sup>	Sub-Total		
<b>Prior Reportable Segments with Supplemental Disclosures</b>								
<b>Plasma</b>	\$ 126,736	-	\$ 126,736	-	-	-	-	\$ 126,736
<b>Blood center</b>	15,121	\$ 39,199	54,320	-	-	-	\$ 1,686	56,006
Apheresis	15,121	39,199	54,320	-	-	-	-	54,320
Whole Blood	-	-	-	-	-	-	1,686	1,686
<b>Hospital</b>	-	-	-	\$ 81,058	\$ 66,799	\$ 147,857	-	147,857
Blood Management Technologies	-	-	-	81,058	-	81,058	-	81,058
Interventional Technologies	-	-	-	-	66,799	66,799	-	66,799
<b>Total net revenues</b>	\$ 141,857	\$ 39,199	\$ 181,056	\$ 81,058	\$ 66,799	\$ 147,857	\$ 1,686	\$ 330,599

**Table 2: Revenue Analysis by New Reportable Segment and Supplemental Disclosures**  
(Dollars in thousands)

	Q4 FY25	Q4 FY24	Reported growth	Currency impact	Acquisitions & Divestitures <sup>5</sup>	Organic growth
<b>Apheresis</b>	\$ 181,056	\$ 193,948	-6.6%	-0.7%	-%	-5.9%
Plasma <sup>1</sup>	141,857	155,182	-8.6%	-0.6%	-%	-8.0%
Other <sup>2</sup>	39,199	38,766	1.1%	-1.4%	-%	2.5%
<b>MedSurg</b>	147,857	131,821	12.2%	-0.8%	4.1%	8.9%
Blood Management Technologies <sup>3</sup>	81,058	76,704	5.7%	-0.7%	-%	6.4%
Interventional Technologies <sup>4</sup>	66,799	55,117	21.2%	-1.0%	9.8%	12.4%
<b>Whole Blood (divested)</b>	1,686	17,521	-90.4%	-0.2%	-53.8%	-36.4%
<b>Total net revenues</b>	\$ 330,599	\$ 343,290	-3.7%	-0.7%	-2.8%	-0.2%

1) Plasma includes Plasma product line. 2) Other includes Platelets, Red Cells and other product lines. 3) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines. 4) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines. 5) Reflects the impact in Blood Center of the divestiture of the Whole Blood product line as of its completion in January 2025 as well as the impact in Hospital/MedSurg of the Esophageal Protection product line acquired as part of the Attune Medical transaction in April 2024 and the Sensor-Guided Technologies product line acquired as part of the OpSens Inc. transaction through the first anniversary of the acquisition in December 2023.

# Q3 Fiscal 2025 Reportable Segment Reconciliation with Supplemental Disclosures

**Table 1: Reconciliation of Prior and New Reportable Segment with Supplemental Disclosures**  
(Dollars in thousands)

	New Reportable Segments with Supplemental Disclosures							
	Apheresis			MedSurg			Whole Blood (divested)	Total net revenues
	Plasma <sup>1</sup>	Other <sup>2</sup>	Sub-Total	Blood Management Technologies <sup>3</sup>	Interventional Technologies <sup>4</sup>	Sub-Total		
<b>Prior Reportable Segments with Supplemental Disclosures</b>								
<b>Plasma</b>	\$ 134,224	-	\$ 134,224	-	-	-	-	\$ 134,224
<b>Blood center</b>	16,700	\$ 38,688	55,388	-	-	-	\$ 14,957	70,345
Apheresis	16,700	38,688	55,388	-	-	-	-	55,388
Whole Blood	-	-	-	-	-	-	14,957	14,957
<b>Hospital</b>	-	-	-	\$ 80,720	\$ 63,253	\$ 143,973	-	143,973
Blood Management Technologies	-	-	-	80,720	-	80,720	-	80,720
Interventional Technologies	-	-	-	-	63,253	63,253	-	63,253
<b>Total net revenues</b>	\$ 150,924	\$ 38,688	\$ 189,612	\$ 80,720	\$ 63,253	\$ 143,973	\$ 14,957	\$ 348,542

**Table 2: Revenue Analysis by New Reportable Segment and Supplemental Disclosures**  
(Dollars in thousands)

	Q3 FY25	Q3 FY24	Reported growth	Currency impact	Acquisitions <sup>5</sup>	Organic growth
<b>Apheresis</b>	\$ 189,612	\$ 200,205	-5.3%	-%	-%	-5.3%
Plasma <sup>1</sup>	150,924	161,494	-6.5%	-0.1%	-%	-6.5%
Other <sup>2</sup>	38,688	38,711	-0.1%	0.1%	-%	-0.2%
<b>MedSurg</b>	143,973	116,230	23.9%	0.1%	11.6%	12.2%
Blood Management Technologies <sup>3</sup>	80,720	73,223	10.2%	0.3%	-%	9.9%
Interventional Technologies <sup>4</sup>	63,253	43,007	47.1%	-0.4%	31.2%	16.3%
<b>Whole Blood (divested)</b>	14,957	19,814	-24.5%	-%	-%	-24.5%
<b>Total net revenues</b>	\$ 348,542	\$ 336,250	3.7%	0.1%	3.9%	-0.3%

1) Plasma includes Plasma product line. 2) Other includes Platelets, Red Cells and other product lines. 3) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines. 4) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines. 5) Reflects the impact in Hospital/MedSurg of the Sensor Guided Technologies product line acquired as part of the OpSens Inc. transaction in December 2023 and the Esophageal Protection product line acquired as part of the Attune Medical transaction in April 2024.

# Q2 Fiscal 2025 Reportable Segment Reconciliation with Supplemental Disclosures

**Table 1: Reconciliation of Prior and New Reportable Segment with Supplemental Disclosures**  
(Dollars in thousands)

	New Reportable Segments with Supplemental Disclosures							
	Apheresis			MedSurg			Whole Blood (divested)	Total net revenues
	Plasma <sup>1</sup>	Other <sup>2</sup>	Sub-Total	Blood Management Technologies <sup>3</sup>	Interventional Technologies <sup>4</sup>	Sub-Total		
<b>Prior Reportable Segments with Supplemental Disclosures</b>								
<b>Plasma</b>	\$ 138,561	-	\$ 138,561	-	-	-	-	\$ 138,561
<b>Blood center</b>	16,258	\$ 38,074	54,332	-	-	-	\$ 14,196	68,528
Apheresis	16,258	38,074	54,332	-	-	-	-	54,332
Whole Blood	-	-	-	-	-	-	14,196	14,196
<b>Hospital</b>	-	-	-	\$ 76,499	\$ 61,923	\$ 138,422	-	138,422
Blood Management Technologies	-	-	-	76,499	-	76,499	-	76,499
Interventional Technologies	-	-	-	-	61,923	61,923	-	61,923
<b>Total net revenues</b>	\$ 154,819	\$ 38,074	\$ 192,893	\$ 76,499	\$ 61,923	\$ 138,422	\$ 14,196	\$ 345,511

**Table 2: Revenue Analysis by New Reportable Segment and Supplemental Disclosures**  
(Dollars in thousands)

	Q2 FY25	Q2 FY24	Reported growth	Currency impact	Acquisitions <sup>5</sup>	Organic growth
<b>Apheresis</b>	\$ 192,893	\$ 197,767	-2.5%	-0.2%	-%	-2.2%
Plasma <sup>1</sup>	154,819	157,578	-1.8%	-0.1%	-%	-1.6%
Other <sup>2</sup>	38,074	40,189	-5.3%	-0.6%	-%	-4.7%
<b>MedSurg</b>	138,422	105,733	30.9%	0.1%	15.0%	15.8%
Blood Management Technologies <sup>3</sup>	76,499	67,192	13.9%	0.3%	-%	13.6%
Interventional Technologies <sup>4</sup>	61,923	38,541	60.7%	-0.2%	41.2%	19.7%
<b>Whole Blood (divested)</b>	14,196	14,683	-3.3%	-%	-%	-3.3%
<b>Total net revenues</b>	\$ 345,511	\$ 318,183	8.6%	-0.1%	5.0%	3.7%

1) Plasma includes Plasma product line. 2) Other includes Platelets, Red Cells and other product lines. 3) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines. 4) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines. 5) Reflects the impact in Hospital/MedSurg of the Sensor Guided Technologies product line acquired as part of the OpSens Inc. transaction in December 2023 and the Esophageal Protection product line acquired as part of the Attune Medical transaction in April 2024.

# Q1 Fiscal 2025 Reportable Segment Reconciliation with Supplemental Disclosures

**Table 1: Reconciliation of Prior and New Reportable Segment with Supplemental Disclosures**  
(Dollars in thousands)

	New Reportable Segments with Supplemental Disclosures							
	Apheresis			MedSurg			Whole Blood (divested)	Total net revenues
	Plasma <sup>1</sup>	Other <sup>2</sup>	Sub-Total	Blood Management Technologies <sup>3</sup>	Interventional Technologies <sup>4</sup>	Sub-Total		
<b>Prior Reportable Segments with Supplemental Disclosures</b>								
<b>Plasma</b>	\$ 135,910	-	\$ 135,910	-	-	-	-	\$ 135,910
<b>Blood center</b>	17,200	\$ 31,894	49,094	-	-	-	\$ 17,151	66,245
Apheresis	17,200	31,894	49,094	-	-	-	-	49,094
Whole Blood	-	-	-	-	-	-	17,151	17,151
<b>Hospital</b>	-	-	-	\$ 70,973	\$ 63,044	\$ 134,017	-	134,017
Blood Management Technologies	-	-	-	70,973	-	70,973	-	70,973
Interventional Technologies	-	-	-	-	63,044	63,044	-	63,044
<b>Total net revenues</b>	\$ 153,110	\$ 31,894	\$ 185,004	\$ 70,973	\$ 63,044	\$ 134,017	\$ 17,151	\$ 336,172

**Table 2: Revenue Analysis by New Reportable Segment and Supplemental Disclosures**  
(Dollars in thousands)

	Q1 FY25	Q1 FY24	Reported growth	Currency impact	Acquisitions <sup>5</sup>	Organic growth
<b>Apheresis</b>	\$ 185,004	\$ 188,783	-2.0%	-0.8%	-%	-1.2%
Plasma <sup>1</sup>	153,110	153,810	-0.5%	-0.5%	-%	-%
Other <sup>2</sup>	31,894	34,973	-8.8%	-2.3%	-%	-6.5%
<b>MedSurg</b>	134,017	102,505	30.7%	-0.6%	17.8%	13.5%
Blood Management Technologies <sup>3</sup>	70,973	64,885	9.4%	-0.6%	-%	10.0%
Interventional Technologies <sup>4</sup>	63,044	37,620	67.6%	-0.4%	48.6%	19.4%
<b>Whole Blood (divested)</b>	17,151	20,044	-14.4%	-0.2%	-%	-14.2%
<b>Total net revenues</b>	\$ 336,172	\$ 311,332	8.0%	-0.7%	5.9%	2.8%

1) Plasma includes Plasma product line. 2) Other includes Platelets, Red Cells and other product lines. 3) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines. 4) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines. 5) Reflects the impact in Hospital/MedSurg of the Sensor Guided Technologies product line acquired as part of the OpSens Inc. transaction in December 2023 and the Esophageal Protection product line acquired as part of the Attune Medical transaction in April 2024.

# Q4 Fiscal 2024 Reportable Segment Reconciliation with Supplemental Disclosures

**Table 1: Reconciliation of Prior and New Reportable Segment with Supplemental Disclosures**  
(Dollars in thousands)

	New Reportable Segments with Supplemental Disclosures							
	Apheresis			MedSurg			Whole Blood (divested)	Total net revenues
	Plasma <sup>1</sup>	Other <sup>2</sup>	Sub-Total	Blood Management Technologies <sup>3</sup>	Interventional Technologies <sup>4</sup>	Sub-Total		
<b>Prior Reportable Segments with Supplemental Disclosures</b>								
<b>Plasma</b>	\$ 139,479	-	\$ 139,479	-	-	-	-	\$ 139,479
<b>Blood center</b>	15,703	\$ 38,766	54,469	-	-	-	\$ 17,520	71,989
Apheresis	15,703	38,766	54,469	-	-	-	-	54,469
Whole Blood	-	-	-	-	-	-	17,520	17,520
<b>Hospital</b>	-	-	-	\$ 76,704	\$ 55,117	\$ 131,821	-	131,821
Blood Management Technologies	-	-	-	76,704	-	76,704	-	76,704
Interventional Technologies	-	-	-	-	55,117	55,117	-	55,117
<b>Total net revenues</b>	\$ 155,182	\$ 38,766	\$ 193,948	\$ 76,704	\$ 55,117	\$ 131,821	\$ 17,520	\$ 343,290

**Table 2: Revenue Analysis by New Reportable Segment and Supplemental Disclosures**  
(Dollars in thousands)

	Q4 FY24	Q4 FY23	Reported growth	Currency impact	Acquisition <sup>5</sup>	Organic growth
<b>Apheresis</b>	\$ 193,948	\$ 182,035	6.5%	-0.9%	-%	7.4%
Plasma <sup>1</sup>	155,182	146,503	5.9%	-0.5%	-%	6.4%
Other <sup>2</sup>	38,766	35,533	9.1%	-2.7%	-%	11.8%
<b>MedSurg</b>	131,821	103,416	27.5%	-0.3%	9.5%	18.3%
Blood Management Technologies <sup>3</sup>	76,704	67,996	12.8%	-0.3%	-%	13.1%
Interventional Technologies <sup>4</sup>	55,117	35,420	55.6%	-0.3%	27.8%	28.1%
<b>Whole Blood (divested)</b>	17,520	18,964	-7.6%	-0.3%	-%	-7.3%
<b>Total net revenues</b>	\$ 343,290	\$ 304,416	12.8%	-0.7%	3.3%	10.2%

1) Plasma includes Plasma product line. 2) Other includes Platelets, Red Cells and other product lines. 3) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines. 4) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines. 5) Reflects the impact in Hospital/MedSurg of the Sensor Guided Technologies product line acquired as part of the OpSens Inc. transaction in December 2023.

# Q3 Fiscal 2024 Reportable Segment Reconciliation with Supplemental Disclosures

**Table 1: Reconciliation of Prior and New Reportable Segment with Supplemental Disclosures**  
(Dollars in thousands)

	New Reportable Segments with Supplemental Disclosures							
	Apheresis			MedSurg			Whole Blood (divested)	Total net revenues
	Plasma <sup>1</sup>	Other <sup>2</sup>	Sub-Total	Blood Management Technologies <sup>3</sup>	Interventional Technologies <sup>4</sup>	Sub-Total		
<b>Prior Reportable Segments with Supplemental Disclosures</b>								
<b>Plasma</b>	\$ 147,640	-	\$ 147,640	-	-	-	-	\$ 147,640
<b>Blood center</b>	13,854	\$ 38,711	52,565	-	-	-	\$ 19,814	72,379
Apheresis	13,854	38,711	52,565	-	-	-	-	52,565
Whole Blood	-	-	-	-	-	-	19,814	19,814
<b>Hospital</b>	-	-	-	\$ 73,223	\$ 43,007	\$ 116,230	-	116,230
Blood Management Technologies	-	-	-	73,223	-	73,223	-	73,223
Interventional Technologies	-	-	-	-	43,007	43,007	-	43,007
<b>Total net revenues</b>	\$ 161,494	\$ 38,711	\$ 200,205	\$ 73,223	\$ 43,007	\$ 116,230	\$ 19,814	\$ 336,250

**Table 2: Revenue Analysis by New Reportable Segment and Supplemental Disclosures**  
(Dollars in thousands)

	Q3 FY24	Q3 FY23	Reported growth	Currency impact	Acquisition <sup>5</sup>	Organic growth
<b>Apheresis</b>	\$ 200,205	\$ 190,217	5.3%	-0.3%	-%	5.6%
Plasma <sup>1</sup>	161,494	152,214	6.1%	-%	-%	6.1%
Other <sup>2</sup>	38,711	38,003	1.9%	-1.6%	-%	3.4%
<b>MedSurg</b>	116,230	94,120	23.5%	0.2%	2.1%	21.3%
Blood Management Technologies <sup>3</sup>	73,223	61,966	18.2%	0.3%	-%	17.8%
Interventional Technologies <sup>4</sup>	43,007	32,154	33.8%	-0.2%	6.1%	27.9%
<b>Whole Blood (divested)</b>	19,814	20,965	-5.5%	0.1%	-%	-5.6%
<b>Total net revenues</b>	\$ 336,250	\$ 305,301	10.1%	-0.2%	0.6%	9.7%

1) Plasma includes Plasma product line. 2) Other includes Platelets, Red Cells and other product lines. 3) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines. 4) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines. 5) Reflects the impact in Hospital/MedSurg of the Sensor Guided Technologies product line acquired as part of the OpSens Inc. transaction in December 2023.

# Q2 Fiscal 2024 Reportable Segment Reconciliation with Supplemental Disclosures

**Table 1: Reconciliation of Prior and New Reportable Segment with Supplemental Disclosures**  
(Dollars in thousands)

	New Reportable Segments with Supplemental Disclosures							
	Apheresis			MedSurg			Whole Blood (divested)	Total net revenues
	Plasma <sup>1</sup>	Other <sup>2</sup>	Sub-Total	Blood Management Technologies <sup>3</sup>	Interventional Technologies <sup>4</sup>	Sub-Total		
<b>Prior Reportable Segments with Supplemental Disclosures</b>								
<b>Plasma</b>	\$ 142,789	6	\$ 142,795	-	-	-	-	\$ 142,795
<b>Blood center</b>	14,789	\$ 40,183	54,972	-	-	-	\$ 14,683	69,655
Apheresis	14,789	40,183	54,972	-	-	-	-	54,972
Whole Blood	-	-	-	-	-	-	14,683	14,683
<b>Hospital</b>	-	-	-	\$ 67,192	\$ 38,541	\$ 105,733	-	105,733
Blood Management Technologies	-	-	-	67,192	-	67,192	-	67,192
Interventional Technologies	-	-	-	-	38,541	38,541	-	38,541
<b>Total net revenues</b>	\$ 157,578	\$ 40,189	\$ 197,767	\$ 67,192	\$ 38,541	\$ 105,733	\$ 14,683	\$ 318,183

**Table 2: Revenue Analysis by New Reportable Segment and Supplemental Disclosures**  
(Dollars in thousands)

	Q2 FY24	Q2 FY23	Reported growth	Currency impact	Organic growth
<b>Apheresis</b>	\$ 197,767	\$ 184,346	7.3%	-0.8%	8.0%
Plasma <sup>1</sup>	157,578	141,756	11.2%	-0.1%	11.3%
Other <sup>2</sup>	40,189	42,590	-5.6%	-2.7%	-2.9%
<b>MedSurg</b>	105,733	93,245	13.4%	-0.4%	13.8%
Blood Management Technologies <sup>3</sup>	67,192	63,670	5.5%	-0.5%	6.0%
Interventional Technologies <sup>4</sup>	38,541	29,575	30.3%	-0.2%	30.5%
<b>Whole Blood (divested)</b>	14,683	19,894	-26.2%	-0.7%	-25.5%
<b>Total net revenues</b>	\$ 318,183	\$ 297,485	7.0%	-0.6%	7.6%

1) Plasma includes Plasma product line. 2) Other includes Platelets, Red Cells and other product lines. 3) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines. 4) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines.

# Q1 Fiscal 2024 Reportable Segment Reconciliation with Supplemental Disclosures

**Table 1: Reconciliation of Prior and New Reportable Segment with Supplemental Disclosures**  
(Dollars in thousands)

	New Reportable Segments with Supplemental Disclosures							
	Apheresis			MedSurg			Whole Blood (divested)	Total net revenues
	Plasma <sup>1</sup>	Other <sup>2</sup>	Sub-Total	Blood Management Technologies <sup>3</sup>	Interventional Technologies <sup>4</sup>	Sub-Total		
<b>Prior Reportable Segments with Supplemental Disclosures</b>								
<b>Plasma</b>	\$ 139,612	9	\$ 139,621	-	-	-	-	\$ 139,621
<b>Blood center</b>	14,198	\$ 34,968	49,166	-	-	-	\$ 20,040	69,206
Apheresis	14,198	34,968	49,166	-	-	-	-	49,166
Whole Blood	-	-	-	-	-	-	20,040	20,040
<b>Hospital</b>	-	-	-	\$ 64,885	\$ 37,620	\$ 102,505	-	102,505
Blood Management Technologies	-	-	-	64,885	-	64,885	-	64,885
Interventional Technologies	-	-	-	-	37,620	37,620	-	37,620
<b>Total net revenues</b>	\$ 153,810	\$ 34,977	\$ 188,787	\$ 64,885	\$ 37,620	\$ 102,505	\$ 20,040	\$ 311,332

**Table 2: Revenue Analysis by New Reportable Segment and Supplemental Disclosures**  
(Dollars in thousands)

	Q1 FY24	Q1 FY23	Reported growth	Currency impact	Organic growth
<b>Apheresis</b>	\$ 188,787	\$ 150,934	25.1%	-1.6%	26.6%
Plasma <sup>1</sup>	153,810	117,111	31.3%	-0.9%	32.2%
Other <sup>2</sup>	34,977	33,824	3.4%	-3.5%	6.9%
<b>MedSurg</b>	102,505	90,929	12.7%	-1.3%	14.0%
Blood Management Technologies <sup>3</sup>	64,885	61,360	5.7%	-1.7%	7.5%
Interventional Technologies <sup>4</sup>	37,620	29,568	27.2%	-%	27.2%
<b>Whole Blood (divested)</b>	20,040	19,595	2.3%	-1.6%	3.9%
<b>Total net revenues</b>	\$ 311,332	\$ 261,458	19.1%	-1.4%	20.5%

1) Plasma includes Plasma product line. 2) Other includes Platelets, Red Cells and other product lines. 3) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines. 4) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines.